

ForPatients

by Roche

Multiple Sclerosis (MS)

A Study To Determine The Effect Of Ocrelizumab On Leptomeningeal Inflammation In Multiple Sclerosis

Trial Status
Withdrawn

Trial Runs In
0 Countries

Trial Identifier
NCT05208840 ML42302

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the evolution of leptomeningeal lesions via leptomeningeal contrast enhancement (LMCE) presence/disappearance after treatment administration in patients with active progressive multiple sclerosis (MS). In addition, this study will investigate if the presence of leptomeningeal inflammation is associated with alterations of B cell repertoire and whether therapy with ocrelizumab will lead to change of B cell repertoire in LMCE-positive patients.

Hoffmann-La Roche
Sponsor

Phase 4
Phase

NCT05208840 ML42302
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
>=18 Years & <= 65 Years

Healthy Volunteers
No
